Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-PSMA-XT in mCRPC
NCT07135102Phase 1Recruiting
- Sponsor
- ACON Laboratories
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 225Ac-PSMA-XT in metastatic castration-resistant prostate cancer (mCRPC), sponsored by ACON Laboratories. Primary endpoints: Treatment Emergent Adverse Events up to 2 years and Dose-limiting toxicity up to 2 years. Started Oct 2024; status: recruiting.
02
Drugs
225Ac-PSMA-XT
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07135102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07135102.